w95a5u

Property	Value
?:abstract	OBJECTIVES: The COVID-19 pandemic presents an urgent need to investigate whether existing drugs can enhance or even worsen prognosis; metformin, a known mammalian target of rapamycin (m-TOR) inhibitor, has been identified as a potential agent. We sought to evaluate mortality benefit among older persons infected with SARS-CoV-2 who were taking metformin as compared to those who were not. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: 775 nursing home residents infected with SARS-CoV-2 who resided in one of the 134 Community Living Centers (CLCs) of the Veterans Health Administration (VHA) during March 1, 2020, to May 13, 2020, were included. METHODS: Using a window of 14 days prior to SARS-CoV-2 testing, bar-coded medication administration records were examined for dispensing of medications for diabetes. The COVID-19-infected residents were divided into 4 groups: (1) residents administered metformin alone or in combination with other medications, (2) residents who used long-acting or daily insulin, (3) residents administered other diabetes medications, and (4) residents not administered diabetes medication, including individuals without diabetes and patients with untreated diabetes. Proportional hazard models adjusted for demographics, hemoglobin A1c, body mass index, and renal function. RESULTS: Relative to those not receiving diabetes medications, residents taking metformin were at significantly reduced hazard of death [adjusted hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.28, 0.84] over the subsequent 30 days from COVID-19 diagnosis. There was no association with insulin (adjusted HR 0.99, 95% CI 0.60, 1.64) or other diabetes medications (adjusted HR 0.71, 95% CI 0.38, 1.32). CONCLUSIONS AND IMPLICATIONS: Our data suggest a reduction in 30-day mortality following SARS-CoV-2 infection in residents who were on metformin-containing diabetes regimens. These findings suggest a relative survival benefit in nursing home residents on metformin, potentially through its mTOR inhibition effects. A prospective study should investigate the therapeutic benefits of metformin among persons with COVID-19. OBJECTIVES: The COVID-19 pandemic presents an urgent need to investigate whether existing drugs can enhance or even worsen prognosis;metformin, a known mammalian target of rapamycin (m-TOR) inhibitor, has been identified as a potential agent We sought to evaluate mortality benefit among older persons infected with SARS-CoV-2 who were taking metformin as compared to those who were not DESIGN: Retrospective cohort study SETTING AND PARTICIPANTS: 775 nursing home residents infected with SARS-CoV-2 who resided in one of the 134 Community Living Centers (CLCs) of the Veterans Health Administration (VHA) during March 1, 2020, to May 13, 2020, were included METHODS: Using a window of 14 days prior to SARS-CoV-2 testing, bar-coded medication administration records were examined for dispensing of medications for diabetes The COVID-19-infected residents were divided into 4 groups: (1) residents administered metformin alone or in combination with other medications, (2) residents who used long-acting or daily insulin, (3) residents administered other diabetes medications, and (4) residents not administered diabetes medication, including individuals without diabetes and patients with untreated diabetes Proportional hazard models adjusted for demographics, hemoglobin A1c, body mass index, and renal function RESULTS: Relative to those not receiving diabetes medications, residents taking metformin were at significantly reduced hazard of death [adjusted hazard ratio (HR) 0 48, 95% confidence interval (CI) 0 28, 0 84] over the subsequent 30 days from COVID-19 diagnosis There was no association with insulin (adjusted HR 0 99, 95% CI 0 60, 1 64) or other diabetes medications (adjusted HR 0 71, 95% CI 0 38, 1 32) CONCLUSIONS AND IMPLICATIONS: Our data suggest a reduction in 30-day mortality following SARS-CoV-2 infection in residents who were on metformin-containing diabetes regimens These findings suggest a relative survival benefit in nursing home residents on metformin, potentially through its mTOR inhibition effects A prospective study should investigate the therapeutic benefits of metformin among persons with COVID-19
is ?:annotates of	<https://research.tib.eu/covid-19/entity/49w95a5u_hasAnnotation_C0013227> <https://research.tib.eu/covid-19/entity/49w95a5u_hasAnnotation_C0376622> <https://research.tib.eu/covid-19/entity/49w95a5u_hasAnnotation_C1999216> <https://research.tib.eu/covid-19/entity/49w95a5u_hasAnnotation_C5203676>
?:creator	<https://research.tib.eu/covid-19/entity/Lally%2C_M._A.%3B_Tsoukas%2C_P.%3B_Halladay%2C_C._W.%3B_O039%2C%3B_Neill%2C_E.%3B_Gravenstein%2C_S.%3B_Rudolph%2C_J._L.> <https://research.tib.eu/covid-19/entity/Lally%2C_Michelle_A%3B_Tsoukas%2C_Philip%3B_Halladay%2C_Christopher_W%3B_O039%2C%3B_Neill%2C_Emily%3B_Gravenstein%2C_Stefan%3B_Rudolph%2C_James_L>
?:journal	J_Am_Med_Dir_Assoc Journal_of_the_American_Medical_Directors_Association
?:license	unk
?:publication_isRelatedTo_Disease	<https://research.tib.eu/covid-19/entity/COVID-19>
is ?:relation_isRelatedTo_publication of	<https://research.tib.eu/covid-19/entity/49w95a5u_HAS_C0013227_TREATS_C0011847> <https://research.tib.eu/covid-19/entity/49w95a5u_HAS_C0025598_INHIBITS_C1307407>
?:source	WHO
?:title	Metformin is Associated with Decreased 30-Day Mortality Among Nursing Home Residents Infected with SARS-CoV2
?:type	<https://research.tib.eu/covid-19/vocab/Publication>
?:who_covidence_id	#1065275 #893994
?:year	2021

Property

Value

?:abstract

OBJECTIVES: The COVID-19 pandemic presents an urgent need to investigate whether existing drugs can enhance or even worsen prognosis; metformin, a known mammalian target of rapamycin (m-TOR) inhibitor, has been identified as a potential agent. We sought to evaluate mortality benefit among older persons infected with SARS-CoV-2 who were taking metformin as compared to those who were not. DESIGN: Retrospective cohort study. SETTING AND PARTICIPANTS: 775 nursing home residents infected with SARS-CoV-2 who resided in one of the 134 Community Living Centers (CLCs) of the Veterans Health Administration (VHA) during March 1, 2020, to May 13, 2020, were included. METHODS: Using a window of 14 days prior to SARS-CoV-2 testing, bar-coded medication administration records were examined for dispensing of medications for diabetes. The COVID-19-infected residents were divided into 4 groups: (1) residents administered metformin alone or in combination with other medications, (2) residents who used long-acting or daily insulin, (3) residents administered other diabetes medications, and (4) residents not administered diabetes medication, including individuals without diabetes and patients with untreated diabetes. Proportional hazard models adjusted for demographics, hemoglobin A1c, body mass index, and renal function. RESULTS: Relative to those not receiving diabetes medications, residents taking metformin were at significantly reduced hazard of death [adjusted hazard ratio (HR) 0.48, 95% confidence interval (CI) 0.28, 0.84] over the subsequent 30 days from COVID-19 diagnosis. There was no association with insulin (adjusted HR 0.99, 95% CI 0.60, 1.64) or other diabetes medications (adjusted HR 0.71, 95% CI 0.38, 1.32). CONCLUSIONS AND IMPLICATIONS: Our data suggest a reduction in 30-day mortality following SARS-CoV-2 infection in residents who were on metformin-containing diabetes regimens. These findings suggest a relative survival benefit in nursing home residents on metformin, potentially through its mTOR inhibition effects. A prospective study should investigate the therapeutic benefits of metformin among persons with COVID-19.
OBJECTIVES: The COVID-19 pandemic presents an urgent need to investigate whether existing drugs can enhance or even worsen prognosis;metformin, a known mammalian target of rapamycin (m-TOR) inhibitor, has been identified as a potential agent We sought to evaluate mortality benefit among older persons infected with SARS-CoV-2 who were taking metformin as compared to those who were not DESIGN: Retrospective cohort study SETTING AND PARTICIPANTS: 775 nursing home residents infected with SARS-CoV-2 who resided in one of the 134 Community Living Centers (CLCs) of the Veterans Health Administration (VHA) during March 1, 2020, to May 13, 2020, were included METHODS: Using a window of 14 days prior to SARS-CoV-2 testing, bar-coded medication administration records were examined for dispensing of medications for diabetes The COVID-19-infected residents were divided into 4 groups: (1) residents administered metformin alone or in combination with other medications, (2) residents who used long-acting or daily insulin, (3) residents administered other diabetes medications, and (4) residents not administered diabetes medication, including individuals without diabetes and patients with untreated diabetes Proportional hazard models adjusted for demographics, hemoglobin A1c, body mass index, and renal function RESULTS: Relative to those not receiving diabetes medications, residents taking metformin were at significantly reduced hazard of death [adjusted hazard ratio (HR) 0 48, 95% confidence interval (CI) 0 28, 0 84] over the subsequent 30 days from COVID-19 diagnosis There was no association with insulin (adjusted HR 0 99, 95% CI 0 60, 1 64) or other diabetes medications (adjusted HR 0 71, 95% CI 0 38, 1 32) CONCLUSIONS AND IMPLICATIONS: Our data suggest a reduction in 30-day mortality following SARS-CoV-2 infection in residents who were on metformin-containing diabetes regimens These findings suggest a relative survival benefit in nursing home residents on metformin, potentially through its mTOR inhibition effects A prospective study should investigate the therapeutic benefits of metformin among persons with COVID-19

is ?:annotates of